Blog

The PsychMed Partner blog.

One post a week, written for therapists, on a current question in psychiatry or mental health. Each post is researched from the published evidence, written in plain language, and lists its sources. The posts are professional education. They are not clinical guidance for any individual patient.

How this blog works

A new article is published every Tuesday. Topics come from questions therapists and their patients raise about psychiatric medication. Each article is checked against the published research before it is published.

Each of the four practice sites has its own blog, and the same weekly topic is written separately for each audience. The psych.us blog is for patients in combined therapy and medication care. The PsychMed Care blog is for patients in medication management. This blog is for therapists: what the evidence says, what belongs in the therapy room, and what belongs to the prescriber. The articles are written by Karel Winner, DNP, PMHNP-BC.

Topics include medicines that affect mood, sleep, and appetite, interactions between psychiatric medicines and medicines prescribed for other conditions, and new studies that change prescribing practice. Each article ends with a sources section listing the studies and regulator publications it is based on. The articles are professional education. They are not clinical guidance for any individual patient.

When a patient asks about a depression headset

The sixth post: the Flow FL-100 at-home tDCS device approved in December 2025, its 174-person remote trial, the uncertainty the FDA stated in writing, and how the work divides between the therapy room and the prescriber.

When a patient asks about Simtriyo

The fifth post: centanafadine, the new ADHD medicine approved in July 2026 and placed in Schedule III in October, what its placebo-controlled trials found, and how the work divides between the therapy room and the prescriber.

Negative symptoms in your therapy room

The fourth post: the CONVOKE trial of a prescription app for the negative symptoms of schizophrenia, its October 2026 FDA clearance, and how the work divides between the therapy room and the prescriber.

Combining CBT-I and medication

The third post: what the 2026 AASM guideline found when CBT-I and insomnia medication were started together, and how the work divides between the therapy room and the prescriber.

Exercise in depression care

The second post: what the January 2026 Cochrane update and two larger reviews found about exercise and depression, and how the work divides between the therapy room and the prescriber.

When your patient starts a GLP-1

The first post: what the two-year regulatory investigation found about GLP-1 medicines, depression, and suicidal thoughts, and what belongs in the therapy room when a patient starts one.

About the prescriber

The record behind these posts: two decades in medicine, six degrees, and a prescribing practice built on full-hour evaluations and careful changes.

Next week

A new article is published here every Tuesday. Topics come from questions therapists and patients raise, and each article is checked against the published research before it is published.